Access cutting-edge iga nephropathy treatment through this clinical trial at a research site in Glendale. Study-provided care at no cost to qualified participants.
Access iga nephropathy specialists in Glendale at no cost
This study follows strict safety protocols and ethical guidelines
All study-related iga nephropathy treatment provided free
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are received and the drug product becomes commercially available while enabling collection of long-term safet
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this iga nephropathy clinical trial in Glendale, AZ
If you're searching for iga nephropathy treatment options in Glendale, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Glendale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced iga nephropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.